Kodiak Sciences reports Q2 results on August 14 carrying one of the more charged short-interest profiles in small-cap biotech, with nearly a fifth of its free float bet against it heading into a binary data catalyst.
Short sellers are firmly dug in. Short interest in KOD runs at 19.8% of the free float — roughly 10.5 million shares — a level that has held remarkably stable over the past six weeks, barely budging week-on-week despite a 9% price rally over the past five sessions. That stability matters: bears have not flinched at the recent strength, suggesting conviction rather than complacency. The borrow market, however, offers shorts no particular squeeze pressure. Cost to borrow is a modest 0.47%, down about 7% on the week, and availability is ample at roughly 546% of short interest — meaning lenders have far more shares available than have been borrowed. For a name with nearly 20% of float short, that lending environment is notably relaxed. Options positioning adds little urgency to the setup; the put/call ratio of 0.47 is only slightly above its 20-day average and barely half a standard deviation elevated, placing options traders in a mildly defensive but far from alarmed stance.
The bull-bear divide on Kodiak is as stark as the clinical history. Bulls point to KSI-101's Phase 3 data — more than 90% of patients reaching retinal dryness by Week 8, alongside meaningful vision gains — as evidence the Antibody Biopolymer Conjugate platform is finally delivering after years of disappointment. JP Morgan raised its price target to $66 from $56 on August 3, maintaining an Overweight rating, and the Street consensus sits at $65, implying roughly 50% upside from the current $43.40 close. Bears counter that Kodiak has failed this story before: the Phase 3 GLEAM and GLIMMER trials and the DAZZLE trial all disappointed, and the company remains deeply cash-consumptive — a negative EV/EBITDA, negative earnings yield, and a Piotroski F-score of zero underline the execution risk baked into the platform story. The August 14 print will carry data from ongoing Phase 3 trials that either validate or reopen those wounds.
The ownership structure adds meaningful context to why short sellers have stayed put despite price appreciation. Baker Bros. Advisors holds 31.9% of shares — a dominance that constrains the float and concentrates risk. Sirenia Capital Management entered as a new holder with 3.5 million shares as of March 31, and T. Rowe Price added nearly 1.3 million shares through June. CFO John Borgeson sold approximately $1 million in stock in early June near $34, a level the stock has since traded well above. Past earnings reactions have been uniformly negative outside one exception — three of the four most recent prints produced single-day declines of 6% to 11%, with five-day moves deteriorating further in two of those cases; the lone outlier was a 27% single-day jump in March 2026.
Thursday's report is therefore less a test of whether Kodiak's science is progressing and more a test of whether the Phase 3 data cadence is strong enough to justify holding a $43 stock against a short base that has shown no inclination to reduce exposure at higher prices.
See the live data behind this article on ORTEX.
Open KOD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
